Key Finding
Dual immunotherapy with nivolumab plus ipilimumab significantly improved tumor response rates compared to monotherapy in dMMR/MSI-H metastatic colorectal cancer, but was accompanied by significantly increased serious toxicity without consistent improvement in progression-free or overall survival across trials.
When you or a loved one is diagnosed with metastatic colorectal cancer, understanding your treatment options can feel overwhelming. A newly published meta-analysis in BMC Cancer examined how different types of immunotherapy — treatments that harness your immune system to fight cancer — compare for a specific group of colorectal cancer patients whose tumors have a feature called dMMR or MSI-H. These molecular markers mean the cancer has trouble repairing its own DNA, which makes it more likely to respond to immunotherapy.
Researchers pooled data from six clinical trials involving 1,460 patients. They looked at two main approaches: single-drug immunotherapy (monotherapy), using drugs like pembrolizumab that block a protein called PD-1, and combination immunotherapy (dual therapy), pairing nivolumab with ipilimumab to block two different immune checkpoints at once.
The findings showed that single-drug immunotherapy was significantly more effective at shrinking tumors than standard chemotherapy, and caused far fewer severe side effects. The combination approach shrank tumors even more effectively than single-drug immunotherapy, but came with a meaningfully higher risk of serious side effects. Importantly, neither approach consistently showed a clear improvement in how long patients lived overall, though the trends generally favored immunotherapy.
For patients navigating these treatments, side effect management becomes a central concern. Immunotherapy can cause fatigue, digestive issues, and inflammation in various organs. This is where integrative support — including acupuncture — may play a meaningful role. Research suggests acupuncture can help manage treatment-related fatigue, nausea, pain, and anxiety, potentially improving quality of life during cancer care.
Always discuss any complementary therapies with your oncology team before starting. To find a qualified acupuncturist experienced in oncology support, look for a licensed practitioner with training in integrative or oncology acupuncture through a recognized professional body.
This meta-analysis (BMC Cancer) synthesized data from six RCTs (n = 1,460) evaluating PD-1/PD-L1 monotherapy and dual immunotherapy (nivolumab plus ipilimumab) versus chemotherapy or monotherapy in dMMR/MSI-H metastatic colorectal cancer. Databases searched included PubMed, Cochrane, Embase, and Web of Science through September 2025; statistical analysis used RevMan 5.3 and Stata 18.0. Monotherapy significantly improved ORR versus chemotherapy (OR = 1.52, 95% CI: 1.02–2.27, P = 0.04) with markedly reduced grade ≥3 adverse events (OR = 0.14, 95% CI: 0.08–0.23, P < 0.00001). Dual immunotherapy improved ORR over monotherapy (OR = 1.77, 95% CI: 1.25–2.49, P = 0.001) but increased toxicity risk (OR = 1.73, 95% CI: 1.22–2.44, P = 0.002). PFS and OS benefits were inconsistent across trials, with all OS confidence intervals crossing 1.0. Clinically, acupuncture may offer adjunctive value in managing immunotherapy-related adverse effects — including fatigue, pain, and gastrointestinal symptoms — supporting patient tolerance and quality of life throughout treatment.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Heat-sensitive moxibustion combined with intrapleural cisplatin achieved a 65% clinical effective rate versus 30% for cisplatin alone, while also significantly reducing bone marrow suppression from 55% to 15% and gastrointestinal reactions from 65% to 30%.
📌 A systematic appraisal of 15 RCTs and 10 systematic reviews found that the methodological quality of existing research on acupuncture for hot flashes and musculoskeletal symptoms in breast cancer patients is too poor to draw reliable conclusions about its effectiveness.
📌 Traditional acupuncture reduced hot flash severity scores by an average of 1.89 points in breast cancer patients compared to just 0.16 points with sham acupuncture, a statistically significant difference (P=.0064) with effects sustained at one-month follow-up.